Chemical and Clinical Analysis of Blood Plasma Components and their Role in the Early Detection of Pathological Disorders
Downloads
Blood plasma is an important diagnostic medium for a variety of pathological disorders, and it has the potential for enabling early-stage disease detection due to its distinct component profile. The present work aims to analyze and summarize the various chemical and clinical components present within blood plasma toward the goal of early-stage disease detection. Existing works have reported on the substantial plasma component profile but suffer from a mostly qualitative discussion of candidate markers. There is still an opportunity to deliver a more quantitative review specifically focused on the analysis of plasma components and on those relevant to early-stage detection of diseases as diverse as cardiovascular and renal disorders, diabetes, and infection.
Early detection of pathological disorders is a prime objective of clinical analyses. Blood is the most widely studied biofluid in clinical diagnostics due to its ease of access and rich information. Blood plasma is of particular interest because it is the liquid portion of blood following complete coagulation and contains a chemical composition reflecting a larger area of the body than other sample types such as serum or whole blood. Because disease typically influences the chemistry of the body, changes in blood plasma composition have the potential to serve as diagnostic biomarkers for clinical pathologies.
1. P. E Geyer, L. M Holdt, D. Teupser, and M. Mann, "Revisiting biomarker discovery by plasma proteomics," 2017. ncbi.nlm.nih.gov
2. D. S. Smirnov, N. J. Ashton, K. Blennow, H. Zetterberg, et al., "Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change," *Acta …*, 2022. springer.com
3. A. Bodaghi, N. Fattahi, and A. Ramazani, "Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases," Heliyon, 2023. cell.com
4. Y. Zhu, "Plasma/Serum Proteomics based on Mass Spectrometry," 2024. ncbi.nlm.nih.gov
5. K. R. Feingold, "Introduction to lipids and lipoproteins," Endotext [internet], 2024. nih.gov
6. R. Cai, J. Ren, M. Guo, T. Wei, Y. Liu, C. Xie, et al., "Dynamic intracellular exchange of nanomaterials' protein corona perturbs proteostasis and remodels cell metabolism," *Proceedings of the National Academy of Sciences*, 2022. pnas.org
7. N. Chander, G. Basha, M. H. Y. Cheng, et al., "Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues," *Therapy Methods &…*, 2023. cell.com
8. M. Ono, M. Kamita, Y. Murakoshi, J. Matsubara et al., "Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry," 2012. ncbi.nlm.nih.gov
9. K. Ekroos, M. Jänis, K. Tarasov, R. Hurme et al., "Lipidomics: A Tool for Studies of Atherosclerosis," 2010. ncbi.nlm.nih.gov
10. A. Lamaziere, C. Wolf, and P. J. Quinn, "Perturbations of Lipid Metabolism Indexed by Lipidomic Biomarkers," 2012. ncbi.nlm.nih.gov
11. C. M. Ghantous, L. Kamareddine, R. Farhat, F. A. Zouein et al., "Advances in Cardiovascular Biomarker Discovery," 2020. ncbi.nlm.nih.gov
12. B. B. Sempasa, "Clotting analysis of blood samples from intensive care unit patients.," 2009. [PDF]
13. I. Awan, "Autoantigens Underlying IgG4 Related Disease," 2017. [PDF]
14. G. Z. Garyfallou, O. Ketebu, S. Şahin, E. B. Mukaetova-Ladinska et al., "Electrochemical Detection of Plasma Immunoglobulin as a Biomarker for Alzheimer’s Disease," 2017. ncbi.nlm.nih.gov
15. X. Liu, Y. Cao, H. Fu, J. Wei et al., "Proteomics Analysis of Serum from COVID-19 Patients," 2021. ncbi.nlm.nih.gov
16. P. E. Geyer, S. Porsdam Mann, P. V. Treit, and M. Mann, "Plasma Proteomes Can Be Reidentifiable and Potentially Contain Personally Sensitive and Incidental Findings," 2021. ncbi.nlm.nih.gov
